Dr. Reeder on Evolving Role of R-CHOP in Aggressive Lymphomas

Craig B. Reeder, MD
Published: Thursday, Oct 20, 2016



Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas, in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

While many agents have efficacy in patients with aggressive lymphomas, Reeder explains that regimens adding cytotoxic drugs to the R-CHOP regimen were less likely to demonstrate benefit. The addition of small molecular inhibitors though, he adds, could have very different results.

Clinical trial results anticipated to be presented at the 2016 ASH Annual Meeting will compare the efficacy between R-CHOP and dose-adjusted EPOG-R, which is infusion chemotherapy, he adds.


Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas, in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

While many agents have efficacy in patients with aggressive lymphomas, Reeder explains that regimens adding cytotoxic drugs to the R-CHOP regimen were less likely to demonstrate benefit. The addition of small molecular inhibitors though, he adds, could have very different results.

Clinical trial results anticipated to be presented at the 2016 ASH Annual Meeting will compare the efficacy between R-CHOP and dose-adjusted EPOG-R, which is infusion chemotherapy, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x